<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">AKINWANDE, OLAGUOKE</style></author><author><style face="normal" font="default" size="100%">PHILIPS, PREJESH</style></author><author><style face="normal" font="default" size="100%">SCOGGINS, CHARLES</style></author><author><style face="normal" font="default" size="100%">MARTIN, ROBERT C.G.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Radioembolization &lt;em&gt;Versus&lt;/em&gt; Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">239-246</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Hepatocellular cancer is a rising dilemma. Patients with unresectable disease may benefit from locoregional therapy. The comparative effectiveness of radioembolization and Doxorubicin-Drug-Eluting-Beads (DEBDOX) has not been established to date. We compared the performance of radioembolization and DEBDOX in the treatment of hepatocellular carcinoma. Patients and Methods: An analysis of our prospectively managed locoregional therapy (LRT) database was performed. Three hundred and fifty-eight patients were treated with LRT for unresectable HCC, out of which 291 were treated with DEBDOX and 67 with Ytrrium-90 (90Y). Comparative toxicity, tumor response, progression-free survival (PFS) and overall survival (OS) were assessed. Propensity score matching was used to reduce treatment-selection bias, producing 48 pairs. Comparative analysis was repeated after propensity matching. Results: Median age was 67 and 65 years for the DEBDOX and 90Y groups respectively (p=0.2). Overall survival favored the DEBDOX group (DEBDOX: 15-months, 90Y: 6-months, p&lt;0.0001). PFS also favored the DEBDOX group (DEBDOX: 15-months, 90Y: 6-months, p&lt;0.0001). All-grade adverse events were similar in both groups, although slightly favoring the DEBDOX group (DEBDOX 10%, 90Y 15%, p=0.1). After propensity score matching, again longer OS was seen with the DEBDOX group (DEBDOX 13 months, 90Y 4 months; p=0.0077). There were also similar all-grade adverse events that slightly favored DEBDOX (DEBDOX 14%, 90Y 20%, p=0.3). Disease control rate was found to be statistically significant, favoring the DEBDOX group (DEBDOX 72%, 90Y 48%; p=0.02). Conclusion: Our observation suggests that DEBDOX outperforms 90Y with superior efficacy and survival with a trend towards lower all-grade toxicity.</style></abstract></record></records></xml>